Dr. Jennifer Brown, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Massachusetts General Hospital

  Residency Hospital, 2001

• Brigham And Womens Hospital

  Fellowship Hospital, 2001

• Dana-farber Cancer Institute

  Fellowship Hospital, 2001

• Massachusetts General Hospital

  Internship Hospital, 1999

• Harvard Medical School

  Medical School, 1998

• Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase, 2015-10-23

• UMBRALISIB IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA OR MANTLE CELL LYMPHOMA: A MULTICENTRE PHASE 1-1B STUDY., 2018-12-14

• A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients, 2020-08-20

• Letter to the Editor: A Phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia, 2014-11-20

• Enhanced activation and expansion of T cells using mechanically soft elastomer fibers., 2018-01-18

• rILYd4, a Human CD59 Inhibitor Enhances Complement Dependent Cytotoxicity of Ofatumumab against Rituximab-resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia, 2011-09-14

• A Phase I dose-ranging study of Bendamustine and Rituximab (BR) in chronic lymphocytic leukemia (CLL) patients with comorbidities, 2016-07-05

• Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome, 2012-08-14

• Outcomes of HLA Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative vs. Reduced-Intensity Conditioning Regimens, 2014-05-28

• Transcriptomic characterization ofSF3B1mutation reveals its pleiotropic effects in chronic lymphocytic leukemia, 2016-11-03

• Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies K. Melvoldet al., 2021-12-18

• Ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) as initial therapy for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial, 2019-06-14

• A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, 2021-03-08

• Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy, 2020-12-03

• Idelalisib immune-related toxicity is associated with improved treatment response, 2021-07-28

• BCL2 suppresses PARP1 function and non-apoptotic cell death, 2012-06-11

• Editorial: New Insights on Bruton's Tyrosine Kinase Inhibitors, 2021-11-23

• Stimulation of Chronic Lymphocytic Leukemia (CLL) Cells with CpG Oligodeoxynucleotide (ODN) Gives Consistent Karyotypic Results among Laboratories: a CLL Research Consortium (CRC)hStudy, 2010-07-30

• Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium, 2013-07-16

• Comparison of Familial and Sporadic Chronic Lymphocytic Leukaemia Using High Resolution Array Comparative Genomic Hybridization, 2010-08-31

• Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia, 2022-07-12

• Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid Malignancies, 2019-09-19

• Growth dynamics in naturally progressing chronic lymphocytic leukaemia, 2019-05-29

• Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study, 2018-03-07

• Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome, 2023-01-09

• PI3Kd-Selective and PI3Ka/d-Combinatorial Inhibitors in Clinical Development for B-Cell Non-Hodgkin Lymphoma, 2017-10-06

• The Evolving Use of PI3 Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia, 2021-05-27

• Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU, and etoposide (CBV) followed by autologous stem cell transplant, 2012-01-03

• Molecular map of chronic lymphocytic leukemia and its impact on outcome, 2022-08-04

• Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia, 2017-01-24

• Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative HLA-Identical Sibling Transplants for Chronic Lymphocytic Leukemia?, 2013-12-07

• Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation, 2016-09-19

• Human CD59 inhibitor sensitizes rituximab resistant lymphoma cells to complement-mediated cytolysis, 2011-01-20

• Risk Factors for Grade 3/4 Transaminase Elevation in Patients with Chronic Lymphocytic Leukemia Treated with Idelalisib, 2020-07-12

• PI3K inhibitors are finally coming of age, 2021-06-14

• Characterization of selective and potent PI3Kd inhibitor (PI3KD-IN-015) for B-Cell malignances, 2016-04-12

• Genomic Approaches to Chronic Lymphocytic Leukemia, 2013-01-30

• Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kd inhibitors, 2023-02-02

• A T Cell Inflammatory Phenotype is Associated with Autoimmune Toxicity of the PI3K Inhibitor Duvelisib in Chronic Lymphocytic Leukemia, 2021-11-06

• Inherited predisposition to chronic lymphocytic leukemia, 2008-10-01

• Rare Germline Variants inATMAre Associated with Chronic Lymphocytic Leukemia, 2017-06-27

• A Phase 2 Study of Concurrent Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas, 2009-03-30

• Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition, 2016-05-20

• PCI-32765, the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials, 2013-02-19

• Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia, 2011-03-14

• Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with and without pembrolizumab maintenance therapy in patients with lymphoma, 2021-10-17

• Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia - Passe Yet?, 2019-07-05

• Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past is Prologue” (Shakespeare), 2022-02-15

• Phosphatidylinositol 3-Kinase (PI3K) d blockade increases genomic instability in B cells, 2017-02-15

• A Phase I Study of Lenalidomide in Combination with Fludarabine and Rituximab in Previously Untreated CLL/SLL, 2010-09-16

• Simultaneous inhibition of Vps34 kinase would enhance PI3Kd inhibitor cytotoxicity in the B-cell malignancies, 2016-07-18

• 4321 Personalization of T cell production for cellular immunotherapy, 2020-06-01

• Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia, 2013-11-12

• Self-Administered, Subcutaneous Alemtuzumab to Treat Residual Disease in Patients With Chronic Lymphocytic Leukemia, 2010-08-30

• Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells, 2015-11-25

• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer, 2023-08-18

• Activation ofNotchandMycsignaling via B cell-restricted depletion ofDnmt3agenerates a consistent murine model of chronic lymphocytic leukemia, 2021-10-22

• Targeting Bruton's Tyrosine Kinase in CLL, 2021-06-23

• Mechanism of EBV inducing anti-tumour immunity and its therapeutic use, 2020-12-23

• Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, 2018-08-18

• Functional testing to characterize and stratify PI3K inhibitor responses in chronic lymphocytic leukemia, 2022-10-14

• Multi-Factor Clustering Incorporating Cell Motility Predicts T Cell Expansion Potential, 2021-04-09

• Clonal architecture ofCXCR4WHIM-like mutations in Waldenstrom Macroglobulinaemia, 2015-12-13

• Enhancer architecture and essential core regulatory circuitry of chronic lymphocytic leukemia, 2018-11-29

• Systematic Genomic Screen for Tyrosine Kinase Mutations in CLL, 2008-08-28

• Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation, 2016-08-08

• Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia, 2022-02-15

• Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia, 2015-07-13

• Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target, 2021-03-24

• Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course, 2021-05-25

• Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia, 2015-12-07

• Integrative Genomic Analysis Implicates Gain ofPIK3CAat 3q26 andMYCat 8q24 in Chronic Lymphocytic Leukemia, 2012-05-23

• MicroRNA Expression Profiling Identifies Activated B Cell Status in Chronic Lymphocytic Leukemia Cells, 2011-03-08

• Targeting transcription regulation in cancer with a covalent CDK7 inhibitor, 2014-06-22

• Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations, 2021-06-24

• miR-29Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors, 2021-05-06

• Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history, 2021-12-01

• Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial, 2018-03-14

• Prognostic score and cytogenetic risk classification for chronic lymphocytic leukemia patients: Center for International Blood and Marrow Transplant Research report, 2019-06-28

• Targeting Constitutively Active STAT3 in Chronic Lymphocytic Leukemia: A Clinical Trial of the STAT3 Inhibitor Pyrimethamine with Pharmacodynamic Analyses, 2021-01-11

• For CLL Cells, There's No Place Like Home, 2019-08-02

• The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF?B activation and induces apoptosis in chronic lymphocytic leukemia B-cells, 2014-03-15

• Prevalence of Familial Malignancy in a Prospectively Screened Cohort of Patients with Lymphoproliferative Disorders, 2008-08-20

• Dipeptidyl Peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia, 2010-09-24

• Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect, 2020-09-16

• Locally disordered methylation forms the basis of intra-tumor methylome variation in chronic lymphocytic leukemia, 2014-12-08

• Evolution and impact of subclonal mutations in chronic lymphocytic leukemia, 2013-02-14

• Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia, 2015-12-06

• Timeliness and Quality of Diagnostic Care for Medicare Recipients with Chronic Lymphocytic Leukemia, 2010-11-08

• Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial, 2017-01-28

• Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice, 2021-11-08